Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Zacks Small-Cap Research

Monday, November 3, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with Betabart (RV-01). The company has also dosed its first patient in a Phase 1/2a clinical study. Additionally, positive clinical updates were provided across four programs, showcasing the company's progress.
Price reaction · baseline $4.88 (2025-11-03 close) · hit after-hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics received IND approval from the FDA.
  • The company initiated a Phase 1/2a clinical study.
  • Positive updates were shared across four programs.

Full Press Release Details

• Analyst Reports
• PDF
• November 3, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• May 9, 2023
• Announcements
• December 19, 2024
• Announcements
• July 16, 2024
• RAD Articles
• October 21, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of Radiopharm's Phase 1 study?

The Phase 1 study focuses on targeting B7H3 with Betabart (RV-01).

When was the IND approval received from the FDA?

The IND approval from the FDA was received on October 20, 2025.

What updates were shared by Radiopharm?

Radiopharm shared positive clinical updates across four programs.

Who was appointed to the Scientific Advisory Board?

Dr. Oliver Sartor was appointed to the Radiopharm Scientific Advisory Board.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Betabart Phase 1 FDA approval clinical study
Last updated: Nov 3, 2025